Journal Article10.1111/j.1468-2982.2007.01359_6.x
Poster
R. Burstein,B. Kosaras,V. Kainz,M. Jakubowski +3 more
- 01 Jun 2007
Vol. 27, pp 628-680
TL;DR: The abstract describes the proceedings of the XIII Congress of the International Headache Society held in Stockholm in 2007.
read more
Abstract: s of the XIII Congress of the International Headache Society/13th IHC 2007 Stockholm, Sweden 28 June – 1 July 2007
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
References
The International Classification of Headache Disorders, 2nd Edition (ICHD-II)--revision of criteria for 8.2 Medication-overuse headache.
Stephen D. Silberstein,Jes Olesen,M. G. Bousser,H. C. Diener,David W. Dodick,M. First,Peter J. Goadsby,H. Göbel,M. J.A. Lainez,J. W. Lance,Richard B. Lipton,G. Nappi,F. Sakai,Jean Schoenen,T. J. Steiner +14 more
TL;DR: The International Classification of Headache Disorders, 2nd Edition (ICHD-II)—revision of criteria for 8.2 Medication-overuse headache is presented.
550
Medications associated with probable medication overuse headache reported in a tertiary care headache center over a 15-year period.
TL;DR: To evaluate the substances associated with medication overuse headache in a headache center, over the course of the past 15 years.
115
Episodic Hypnic Headache
TL;DR: The review of the published cases suggests that hypnic headache tends to be a chronic unremitting disorder.
Aspirin and tension-type headache.
TL;DR: ASA is well known as a headache medication, figuring as a possible treatment choice in tension-type headache but also in acute migraine attacks and a new Aspirin formulation with a greater rapidity of action has been introduced.
Long-term benefits of botulinum toxin type A (BOTOX) in chronic daily headache: a five-year long experience
TL;DR: Five-year long experience with BoNT-A therapy shows that it appears to be an efficacious new therapeutic choice in the prophylaxis of CDH, especially for patients not responding to previous prophYLactic treatments.